Last 2,227
Change Today 0.00 / 0.00%
Volume 0.0
KMDA On Other Exchanges
Symbol
Exchange
Tel Aviv
NASDAQ GS
As of 9:24 AM 07/27/14 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Open
$2,240
Previous Close
$2,227
Day High
$2,240
Day Low
$2,225
52 Week High
03/3/14 - $6,200
52 Week Low
07/16/14 - $2,211
Market Cap
800.8M
Average Volume 10 Days
119.3K
EPS TTM
$-0.02
Shares Outstanding
36.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. Its respiratory disease products, including Glassia used in augmentation therapy for patients with emphysema secondary to congenital alpha-1 antitrypsin deficiency; and Bramitob to manage chronic pulmonary infection. The company’s immunoglobulin products include KamRAB for prophylaxis against rabies infection; KamRho(D)IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; Snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. In addition, it provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of proper level in the patient’s blood plasma. Further, the company offers Heparin Lock Flush to maintain patency of indwelling IV catheter; Human Transferrin for diagnostic assays and cell cultures; and Kamacaine 0.5% used as anesthesia or analgesia for surgery, obstetrical procedures, and diagnostic and therapeutic procedures, as well as spinal anesthesia for surgery. Additionally, it offers coagulation factors, including Factor VIII, Factor IX, and Bupivacaine. The company also develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary disease, graft-versus-host diseases, and transplantations. It has a collaboration partnership with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States and Europe; and distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

289 Employees
Last Reported Date: 03/26/14
Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $1.5M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $347.0K
Vice President of Operations and Plant Manage...
Total Annual Compensation: $232.0K
Senior Vice President of Quality & Regulatory...
Total Annual Compensation: $174.0K
Vice President of Clinical Development & IP
Total Annual Compensation: $177.0K
Compensation as of Fiscal Year 2013.

kamada ltd (KMDA) Key Developments

Kamada Ltd. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 10:30 AM

Kamada Ltd. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 10:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Gil Efron, Chief Financial Officer and Principal Accounting Officer.

Kamada Ltd. Announces Results of Alpha-1 Antitrypsin from the Phase II/III Pivotal Clinical Trial in Europe and Canada

Kamada Ltd. announced preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of the company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema). The endpoints selected for this trial were based on scientific advice from the European Medicines Agency (EMA) and include those deemed to be clinically meaningful, such as frequency, time to first, duration and severity of exacerbation events, among others. A preliminary analysis of the results indicates clinically meaningful signs for inhaled AAT efficacy as well as additional positive signs in specific study populations. In a very important secondary end point, frequency of severe exacerbation was approximately 50% lower in the AAT group versus placebo. Forced Expiration Volume in one second (FEV1) data, a secondary and safety endpoint, indicated positive trends in improvement. Additionally, the data showed efficacy in certain subsets of patient populations. Safety data of inhaled AAT was supportive and consistent with previous reports and demonstrated a high safety and tolerability profile. Based on the initial review, the Company believes that some of the data may support the issuance of new patents for the product. The Company continues to analyze the data in accordance with the statistical plan and intends to release a more profound set of results in third quarter of 2014.

Kamada Ltd. - Special Call

To discuss results from its phase 2/3 clinical trial of its proprietary inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) in Europe and Canada

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 2,227.00 0.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €38.97 EUR +0.165
View Industry Companies
 

Industry Analysis

KMDA

Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit www.kamada.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.